Summary

Vitiligo Treatment Market Research Report Information by Type (Segmental Vitiligo, Non-Segmental Vitiligo), By Treatment (Therapy, Surgery, Medication), By End-User (Hospitals, Ambulatory Clinics, Others), and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2030


Market Overview
The Vitiligo Treatment Market industry is expected to grow at a compound annual growth rate (CAGR) of 6.20% over the forecast period. The growing relevance of aesthetic appeal and awareness, the rising prevalence of vitligo, and innovations in treatment options are propelling the industry forward.
Consumers' beauty consciousness has increased significantly in recent years because of expanding awareness of various aesthetic treatments, rising per capita income, and the adoption of internet platforms. According to the International Society of Aesthetic Plastic Surgery (ISAPS), worldwide total non-surgical procedures increased by 27.3% between 2015 and 2019. Furthermore, the American Society of Plastic Surgeons (ASPS) reports that the number of minimally invasive cosmetic operations increased by around 200% between 2000 and 2017. Furthermore, around 15.9 million minimally invasive cosmetic operations were performed in 2018, up 2% from 2017.

Market Segment insights
The Vitiligo Treatment Market is divided into two types: segmental vitiligo and non-segmental vitiligo.
The market is segmented based on treatment options such as therapy, surgery, and medication.
The market is segmented by end user, which includes hospitals, ambulatory clinics, and others.

Regional insights
The North American Vitiligo Treatment Market held the biggest market share in 2023. Due to improved healthcare infrastructure and increased awareness of skin problems. The region's significant concentration on research and development has resulted in the launch of novel treatments such as enhanced phototherapy, biologics, and topical medicines.
The European Vitiligo Treatment Market is predicted to account for the second-largest market share due to favorable health legislation and a tendency toward integrating Vitiligo Treatment. Furthermore, the German Vitiligo Treatment Market was found to have the greatest market share, while the France Vitiligo Treatment Market is predicted to be the fastest-growing market in the European area.
The Asia-Pacific Vitiligo Treatment market is predicted to develop at the quickest rate between 2024 and 2030. This is due to improved healthcare infrastructure, combined with increased healthcare expenditures, which allow for better access to innovative therapies. Furthermore, the increasing frequency of vitiligo and the growing need for cosmetic and dermatological therapies are key motivators.

Major Players
Incyte (US), Bausch Health Companies Inc. (Canada), Koninklijke Philips N.V. (Netherlands), Reddy's Laboratories Ltd. (India), Strata Skin Sciences (US), Clinuvel Pharmaceuticals Ltd. (Australia), ISSAR Pharmaceuticals Pvt. Ltd. (India), Kernel Medical Equipment CO., LTD. (China), LightSources (US), and Roivant Sciences Ltd. (Switzerland) are among the key companies in the Vitiligo Treatment Market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
1.1.1 MARKET SYNOPSIS
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 LIST OF ASSUMPTIONS
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA MINING
3.3 SECONDARY RESEARCH
3.4 PRIMARY RESEARCH
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 GROWING IMPORTANCE OF THE AESTHETIC APPEAL AND AWARENESS
4.2.2 INCREASING PREVALENCE OF VITLIGO
4.3 RESTRAINTS
4.3.1 LACK OF TRAINED PROFESSIONALS
4.4 OPPORTUNITIES
4.4.1 RISING NUMBER OF CLINICAL TRIALS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE VITILIGO TREATMENT MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON REGION
5.3.3 IMPACT ON DEMAND AND SUPPLY
6 GLOBAL VITILIGO TREATMENT MARKET, BY TYPE
6.1 OVERVIEW
6.2 SEGMENTAL VITILIGO
6.3 NON-SEGMENTAL VITILIGO
7 GLOBAL VITILIGO TREATMENT MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 THERAPY
7.2.1 DEPIGMENTATION
7.2.2 LIGHT
7.3 SURGERY
7.3.1 SKIN GRAFTING
7.3.2 BLISTER GRAFTING
7.3.3 MICRO-PIGMENTATION
7.4 MEDICATION
7.4.1 TOPICAL CORTICOSTEROIDS
7.4.2 IMMUNOSUPPRESSIVE
8 GLOBAL VITILIGO TREATMENT MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 AMBULATORY CLINICS
8.4 OTHERS
9 GLOBAL VITILIGO TREATMENT MARKET, BY REGION
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 UK
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 REST OF EUROPE
9.4 ASIA-PACIFIC
9.4.1 CHINA
9.4.2 JAPAN
9.4.3 INDIA
9.4.4 SOUTH KOREA
9.4.5 AUSTRALIA
9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
9.5.1 MIDDLE EAST
9.5.2 AFRICA
9.5.3 LATIN AMERICA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPETITIVE BENCHMARKING
10.3 MAJOR GROWTH STRATEGY IN VITILIGO TREATMENT MARKET
10.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN VITILIGO TREATMENT MARKET
10.5 KEY DEVELOPMENT ANALYSIS
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 PRODUCT APPROVALS/PRODUCT LAUNCHES/DRUG PIPELINE
10.6.2 MERGERS & ACQUISITIONS
10.7 MAJOR PLAYERS SALES ANALYSIS
10.7.1 SALES & OPERATING INCOME, 2022
10.7.2 MAJOR PLAYERS R&D ANALYSIS, 2022
11 COMPANY PROFILE
11.1 INCYTE
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 BAUSCH HEALTH COMPANIES INC.
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 KONINKLIJKE PHILIPS N.V.
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.3.6 KEY STRATEGIES
11.4 DR. REDDY'S LABORATORIES LTD.
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.4.6 KEY STRATEGIES
11.5 STRATA SKIN SCIENCES
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIES
11.6 CLINUVEL PHARMACEUTICALS LTD
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.6.6 KEY STRATEGIES
11.7 ISSAR PHARMACEUTICALS PVT. LTD.
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL ANALYSIS
11.7.3 PRODUCTS OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 KEY STRATEGIES
11.8 KERNEL MEDICAL EQUIPMENT CO., LTD.
11.8.1 COMPANY OVERVIEWS
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 KEY STRATEGIES
11.9 LIGHTSOURCES
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL ANALYSIS
11.9.3 PRODUCTS OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIES
11.10 ROIVANT SCIENCES LTD.
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL ANALYSIS
11.10.3 PRODUCTS OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 PRODUCTS OFFERED
11.10.6 KEY STRATEGIES
12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS